• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用网络药理学和分子对接技术,并通过蛋白质组学和实验来验证益骨汤(YGD)对骨质疏松小鼠关键基因表达的影响。

Using network pharmacology and molecular docking technology, proteomics and experiments were used to verify the effect of Yigu decoction (YGD) on the expression of key genes in osteoporotic mice.

作者信息

Yan Kun, Zhang Rui-Kun, Wang Jia-Xin, Chen Hai-Feng, Zhang Yang, Cheng Feng, Jiang Yi, Wang Min, Wu Ziqi, Chen Xiao-Gang, Chen Zhi-Neng, Li Gui-Jin, Yao Xin-Miao

机构信息

The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.

出版信息

Ann Med. 2025 Dec;57(1):2449225. doi: 10.1080/07853890.2024.2449225. Epub 2025 Jan 3.

DOI:10.1080/07853890.2024.2449225
PMID:39749683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11703118/
Abstract

BACKGROUND

Yigu decoction (YGD) is a traditional Chinese medicine prescription for the treatment of osteoporosis, although many clinical studies have confirmed its anti-OP effect, but the specific mechanism is still not completely clear.

METHODS

In this study, through the methods of network pharmacology and molecular docking, the material basis and action target of YGD in preventing and treating OP were analyzed, and the potential target and mechanism of YGD in preventing and treating OP were clarified by TMT quantitative protein and experiment.

RESULTS

Network pharmacology and molecular docking revealed that the active components of YGD were mainly stigmasterol and flavonoids. Molecular docking mainly studied the strong binding ability of stigmasterol to the target. Animal proteomics verified the related mechanism of YGD in preventing and treating OP. Based on the KEGG enrichment of network pharmacology and histology, our animal experiments verified that YGD may play a role in the treatment of OP by mediating hif1- α/vegf/glut1 signal pathway.

CONCLUSIONS

YGD prevention and treatment of OP may be achieved by interfering with multiple targets. This study confirmed that it may promote osteoblast proliferation and protect osteoblast function by up-regulating the expression of proteins related to HIF signal pathway.

摘要

背景

益骨汤(YGD)是一种用于治疗骨质疏松症的中药方剂,虽然许多临床研究已证实其抗骨质疏松作用,但其具体机制仍不完全清楚。

方法

本研究通过网络药理学和分子对接方法,分析益骨汤防治骨质疏松症的物质基础和作用靶点,并通过TMT定量蛋白质组学和实验阐明益骨汤防治骨质疏松症的潜在靶点和机制。

结果

网络药理学和分子对接显示,益骨汤的活性成分主要为豆甾醇和黄酮类化合物。分子对接主要研究了豆甾醇与靶点的强结合能力。动物蛋白质组学验证了益骨汤防治骨质疏松症的相关机制。基于网络药理学和组织学的KEGG富集分析,我们的动物实验验证了益骨汤可能通过介导hif1-α/vegf/glut1信号通路在骨质疏松症治疗中发挥作用。

结论

益骨汤防治骨质疏松症可能是通过干扰多个靶点实现的。本研究证实,其可能通过上调与HIF信号通路相关的蛋白质表达来促进成骨细胞增殖并保护成骨细胞功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/6600ede63aef/IANN_A_2449225_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/35e2244d5309/IANN_A_2449225_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/dce99a7b2314/IANN_A_2449225_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/ae96dceb3be9/IANN_A_2449225_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/2f785d1c8d5e/IANN_A_2449225_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/c16d51a9f670/IANN_A_2449225_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/6600ede63aef/IANN_A_2449225_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/35e2244d5309/IANN_A_2449225_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/dce99a7b2314/IANN_A_2449225_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/ae96dceb3be9/IANN_A_2449225_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/2f785d1c8d5e/IANN_A_2449225_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/c16d51a9f670/IANN_A_2449225_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ba0/11703118/6600ede63aef/IANN_A_2449225_F0006_C.jpg

相似文献

1
Using network pharmacology and molecular docking technology, proteomics and experiments were used to verify the effect of Yigu decoction (YGD) on the expression of key genes in osteoporotic mice.运用网络药理学和分子对接技术,并通过蛋白质组学和实验来验证益骨汤(YGD)对骨质疏松小鼠关键基因表达的影响。
Ann Med. 2025 Dec;57(1):2449225. doi: 10.1080/07853890.2024.2449225. Epub 2025 Jan 3.
2
Quantitative proteomics reveals the effect of Yigu decoction (YGD) on protein expression in bone tissue.定量蛋白质组学揭示了益骨汤(YGD)对骨组织中蛋白质表达的影响。
Clin Proteomics. 2021 Oct 12;18(1):24. doi: 10.1186/s12014-021-09330-0.
3
Uncovering the action mechanism of Shenqi Tiaoshen formula in the treatment of chronic obstructive pulmonary disease through network pharmacology, molecular docking, and experimental verification.通过网络药理学、分子对接和实验验证揭示参芪调神方治疗慢性阻塞性肺疾病的作用机制。
J Tradit Chin Med. 2024 Aug;44(4):770-783. doi: 10.19852/j.cnki.jtcm.20240610.002.
4
Network Pharmacology Studies on the Molecular Mechanism of Hashimoto's Thyroiditis Treated with Shutiao Qiji Decoction.基于网络药理学探讨芍芪杞积汤治疗桥本甲状腺炎的分子机制
Comb Chem High Throughput Screen. 2024;27(19):2899-2911. doi: 10.2174/0113862073259714231012070100.
5
The therapeutic mechanism of Compound Lurong Jiangu Capsule for the treatment of cadmium-induced osteoporosis: network pharmacology and experimental verification.复方鹿蓉健骨胶囊治疗镉致骨质疏松症的作用机制:网络药理学与实验验证。
Front Endocrinol (Lausanne). 2024 Jul 10;15:1331488. doi: 10.3389/fendo.2024.1331488. eCollection 2024.
6
[Research on the mechanism of shengxian and jinshuiliujun decoction in treating silicosis based on network pharmacology].基于网络药理学的升陷金水六君汤治疗矽肺作用机制研究
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2024 Jul 20;42(7):487-497. doi: 10.3760/cma.j.cn121094-20230818-00037.
7
Mechanism of action of Sambucus williamsii Hance var. miquelii in the treatment of osteoporosis analyzed by UHPLC-HRMS/MS combined network pharmacology and experimental validation.采用 UHPLC-HRMS/MS 联合网络药理学和实验验证分析黑果腺肋花楸治疗骨质疏松症的作用机制。
Fitoterapia. 2024 Jul;176:106003. doi: 10.1016/j.fitote.2024.106003. Epub 2024 May 8.
8
Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking.基于网络药理学和分子对接技术探究黄精治疗骨质疏松症的分子机制。
Front Endocrinol (Lausanne). 2022 Jan 5;12:815891. doi: 10.3389/fendo.2021.815891. eCollection 2021.
9
Exploring the mechanism of Xiaoqinglong decoction in the treatment of infantile asthma based on network pharmacology and molecular docking.基于网络药理学和分子对接技术探讨小青龙汤治疗小儿哮喘的作用机制。
Medicine (Baltimore). 2023 Jan 13;102(2):e32623. doi: 10.1097/MD.0000000000032623.
10
Network pharmacology and molecular docking to explore the treatment potential and molecular mechanism of Si-Miao decoction against gouty arthritis.网络药理学和分子对接探索四妙汤治疗痛风性关节炎的潜力及作用机制。
Medicine (Baltimore). 2024 May 31;103(22):e38221. doi: 10.1097/MD.0000000000038221.

引用本文的文献

1
Risk relationship between osteoporosis and plasma proteins.骨质疏松症与血浆蛋白之间的风险关系。
Medicine (Baltimore). 2025 Aug 29;104(35):e44105. doi: 10.1097/MD.0000000000044105.
2
Network Pharmacology and Experimental Validation-based Investigation of the Underlying Mechanism of Yi-Yi-Fu-Zi-Bai-Jiang-San of Nasopharyngeal Carcinoma.基于网络药理学和实验验证的鼻咽癌益苡附子败酱散作用机制研究
J Cancer. 2025 Mar 29;16(7):2212-2232. doi: 10.7150/jca.109758. eCollection 2025.
3
Editorial: Traditional clinical symptoms and signs: how can they be used to investigate medications in the context of pharmacology?

本文引用的文献

1
Targeting YAP1-regulated Glycolysis in Fibroblast-Like Synoviocytes Impairs Macrophage Infiltration to Ameliorate Diabetic Osteoarthritis Progression.靶向成纤维样滑膜细胞中 YAP1 调控的糖酵解作用可抑制巨噬细胞浸润,从而改善糖尿病性骨关节炎的进展。
Adv Sci (Weinh). 2024 Feb;11(5):e2304617. doi: 10.1002/advs.202304617. Epub 2023 Dec 3.
2
ER-β accelerates the process of primary osteoporosis by promoting VEGFA-mediated apoptosis of osteoblasts.雌激素受体-β通过促进血管内皮生长因子A介导的成骨细胞凋亡加速原发性骨质疏松症进程。
Genomics. 2023 Nov;115(6):110743. doi: 10.1016/j.ygeno.2023.110743. Epub 2023 Nov 13.
3
Anti-osteoporotic drugs affect the pathogenesis of gut microbiota and its metabolites: a clinical study.
社论:传统临床症状和体征:在药理学背景下如何用于研究药物?
Front Pharmacol. 2025 Mar 31;16:1588000. doi: 10.3389/fphar.2025.1588000. eCollection 2025.
抗骨质疏松药物影响肠道微生物群及其代谢物的发病机制:一项临床研究。
Front Cell Infect Microbiol. 2023 Jul 4;13:1091083. doi: 10.3389/fcimb.2023.1091083. eCollection 2023.
4
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.唑来膦酸(普罗力)治疗绝经后妇女骨质疏松症的临床疗效:与双膦酸盐、选择性雌激素受体调节剂(SERM)和安慰剂的系统评价和网络荟萃分析。
Calcif Tissue Int. 2023 Jun;112(6):631-646. doi: 10.1007/s00223-023-01078-z. Epub 2023 Apr 5.
5
Psoralen prevents the inactivation of estradiol and treats osteoporosis via covalently targeting HSD17B2.补骨脂素通过共价靶向17β-羟类固醇脱氢酶2(HSD17B2)来防止雌二醇失活并治疗骨质疏松症。
J Ethnopharmacol. 2023 Jul 15;311:116426. doi: 10.1016/j.jep.2023.116426. Epub 2023 Mar 28.
6
Protective effects of oridonin against osteoporosis by regulating immunity and activating the Wnt3a/β-catenin/VEGF pathway in ovariectomized mice.冬凌草甲素通过调节免疫和激活 Wnt3a/β-连环蛋白/VEGF 通路防治去卵巢小鼠骨质疏松症。
Int Immunopharmacol. 2023 May;118:110011. doi: 10.1016/j.intimp.2023.110011. Epub 2023 Mar 14.
7
Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK.异土木香内酯通过抑制 RANKL 与 RANK 的结合来减轻骨丢失。
Biochem Pharmacol. 2023 May;211:115502. doi: 10.1016/j.bcp.2023.115502. Epub 2023 Mar 13.
8
The role of autophagy in bone metabolism and clinical significance.自噬在骨代谢中的作用及其临床意义。
Autophagy. 2023 Sep;19(9):2409-2427. doi: 10.1080/15548627.2023.2186112. Epub 2023 Mar 8.
9
Current Management of Hip Fracture.髋部骨折的现行处理方法。
Medicina (Kaunas). 2022 Dec 23;59(1):26. doi: 10.3390/medicina59010026.
10
HIF-1α mediates osteoclast-induced disuse osteoporosis via cytoophidia in the femur of mice.HIF-1α 通过小鼠股骨中的细胞丝状伪足介导破骨细胞诱导的废用性骨质疏松症。
Bone. 2023 Mar;168:116648. doi: 10.1016/j.bone.2022.116648. Epub 2022 Dec 21.